HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $6 price target.
HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $6 price target.